We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humana and Sprouts Farmers Market have been highlighted as Zacks Bull and Bear of the Day
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 20, 2026 – Zacks Equity Research shares Humana (HUM - Free Report) as the Bull of the Day and Sprouts Farmers Market (SFM - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Palo Alto Networks, Inc. (PANW - Free Report) , CrowdStrike Holdings, Inc. (CRWV - Free Report) and Fortinet, Inc. (FTNT - Free Report)
Humana, a Zacks Rank #1 (Strong Buy), has gone from the most beaten-down name in managed care to one of the market's best performers in the span of a single year.
The company that investors abandoned over a collapse in its Medicare Advantage Star Ratings has spent 2026 methodically repairing the problem, and the evidence is now showing up in both the earnings estimates and the stock.
Shares have gained roughly 48% year to date and set a new 52-week high earlier this week, leaving both the Zacks Medical sector and the broader HMO group well behind. A stock that rallies this hard while analysts are still raising their numbers is precisely the combination we look for in a market leader.
Humana is part of the Zacks Medical – HMOs industry group, which currently ranks in the top 12% out of approximately 250 Zacks Ranked Industries. Because it is ranked in the top half of all Zacks Ranked Industries, we expect this group to outperform over the next 3 to 6 months.
Stocks in this industry are projected to experience above-average earnings growth, which should serve as a powerful foundation to higher stock prices over time.
Historical research studies suggest that approximately half of a stock's price appreciation is due to its industry grouping. In fact, the top 50% of Zacks Ranked Industries outperforms the bottom 50% by a factor of more than 2 to 1.
It's no secret that investing in stocks that are part of leading industry groups can give us a leg up relative to the market. By focusing on leading stocks within the top 50% of Zacks Ranked Industries, we can dramatically improve our odds of success.
Company Description
Humana is one of the largest Medicare Advantage insurers in the United States. The company operates through two segments. Its Insurance segment offers Medicare Advantage, stand-alone Medicare Part D prescription drug plans and Medicaid coverage, while its CenterWell segment provides senior-focused primary care, home health and pharmacy services.
That combination makes Humana unusually concentrated in the Medicare population, which is both its greatest source of growth and the reason it suffered so badly when its quality scores slipped.
The Star Ratings story is the heart of this turnaround. Medicare pays quality bonuses to plans rated four stars or higher, and Humana's ratings deteriorated sharply in the 2025 cycle, creating a revenue headwind that has weighed on 2026 earnings. Management responded with an operational overhaul aimed at quality metrics, and the payoff arrived in October.
Based on final 2027 Star Ratings data from CMS, Humana posted a member-weighted rating of 4.17 — approaching the best in its history — and exceeded its goal of top-quartile results, defined as Stars revenue per member at least 10% above the median of Centene, CVS, Elevance, HCSC and UnitedHealth. Those ratings determine bonus payments in 2028, giving investors a clear line of sight on a meaningful tailwind.
CenterWell continues to build quietly underneath. Senior primary care added roughly 146,800 patients this year, a 30% increase that includes the MaxHealth acquisition, while Medicaid membership grew about 7% and now spans 13 states.
A Smaller Loss and a Higher Floor
Humana reported third-quarter results on November 6th that beat on both lines. The company posted an adjusted loss of $0.70 per share against the Zacks Consensus Estimate for a loss of $1.03, a surprise of roughly 32%, and it has now topped the consensus in each of the last four quarters. Revenue climbed about 26% to $41.2 billion, ahead of expectations near $40.9 billion.
The cost line drove the beat. The Insurance segment benefit ratio came in at 93.7%, better than management's guidance of slightly above 94%, and the consolidated adjusted operating cost ratio improved to 11.2% from 11.8% a year earlier. Medical cost trend is running at the low end of the expected 7% to 8% range for 2026, and management says individual Medicare Advantage pretax margin is on track to double this year excluding the Stars headwind.
Management raised its 2026 adjusted earnings floor to at least $9.50 per share from $9.00. Just as important for next year, the company now expects 2027 Medicare Advantage membership to grow, a reversal from its earlier flat-to-down view, with retention and new sales in the current enrollment period running ahead of plan.
Analysts have moved higher with management. The Zacks Consensus Estimate for 2026 stands at $9.52 per share, having climbed more than 4% over the past three months. The more striking figure is next year: the 2027 consensus sits at $17.26, which would represent growth of more than 81% on revenue of roughly $171.5 billion. Estimates rising for both the current year and the recovery year are the engine behind the Zacks Rank #1.
Let's Get Technical
Humana shares have been in a persistent uptrend throughout 2026, trading above an upward-sloping 200-day (red line) moving average and carving out a steady series of higher highs and higher lows. A recent pullback presents an intriguing buying opportunity.
Only stocks in genuinely powerful uptrends make this type of move and sustain it. This is the kind of name we want in the portfolio — one that is trending well and receiving positive earnings estimate revisions at the same time.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. As long as that trend remains intact and Humana continues to deliver earnings beats, the stock should continue its bullish run.
Bottom Line
Backed by a leading industry group, four straight earnings beats, a raised guidance floor and a Star Ratings recovery that sets up a multi-year earnings rebuild, it isn't difficult to see why this company is a compelling investment right now. Humana carries a Zacks Rank #1 (Strong Buy) driven by favorable estimate momentum, along with an 'A' Zacks VGM Style Score.
Robust fundamentals combined with a strong technical trend certainly justify adding shares to the mix. If you haven't already done so, be sure to put HUM on your watchlist.
Sprouts Farmers Market operates specialty grocery stores focused on fresh, natural and organic food across the United States. The company ended its most recent quarter with 504 stores in 25 states, built around a produce-centric layout and a growing private label program.
For several years, Sprouts was one of the best stories in food retail. Its health-and-wellness positioning attracted a loyal, higher-income customer, its smaller-format stores generated strong returns, and steady comparable sales growth paired with an aggressive opening schedule earned the stock a premium multiple.
That story has broken down in 2026. Traffic is falling, the customer is migrating toward value retailers, and management has concluded that the only way to win shoppers back is to invest heavily in price. That may well be the right strategic call, but it comes at a direct cost to margins, and the earnings outlook is being reset accordingly.
The Zacks Rundown
Sprouts has been underperforming the market badly. A Zacks Rank #5 (Strong Sell), the stock has fallen roughly 41% year to date and recently traded under $50, registering a 52-week low. Shares collapsed roughly 23% in a single session following the third-quarter report on October 29th.
The company is part of the Zacks Food – Natural Foods Products industry group, which currently ranks in the bottom 6% out of approximately 250 industries. Because this industry is ranked in the bottom half of all Zacks Ranked Industries, we expect it to underperform the market over the next 3 to 6 months, just as it has over the past year.
While individual stocks have the ability to outperform even when included in weak industries, their industry association serves as a headwind for any potential rallies. Stocks in this group are also expected to post below-average earnings growth. With much better alternatives in the current market environment, this stock should be avoided.
Traffic Is the Problem
Sprouts reported third-quarter results that missed on both lines. Earnings of $1.21 per share came in just below the $1.22 Zacks Consensus Estimate and slipped from the year-ago quarter, while revenue of $2.30 billion grew 4.7% but fell about 1% short of expectations. Revenue growth came entirely from new stores, with a record 15 openings in the quarter.
The underlying store base went backward. Comparable store sales fell 0.9%, as comparable transactions dropped 3.3% and were only partially offset by a 2.5% increase in average basket size. Management said comps softened through August and September and did not recover as year-over-year comparisons eased, a detail that argues against a temporary disruption.
Margins compressed across the board. Gross margin fell 50 basis points to 38.2% on higher shrink and elevated fuel costs, while EBIT margin declined roughly 60 basis points to 6.6% and operating income fell 2.9%. Management noted that weakness is concentrated among less-engaged, somewhat lower-income customers, but also acknowledged modest softening among its core shoppers — the customers Sprouts can least afford to lose.
The guidance reset is where the real damage was done. Full-year comparable sales are now expected to decline about 1.7%, down from a prior range of negative 0.5% to positive 0.5%. Net sales growth was cut to about 4.3% from 5.5% to 6.5%, and earnings guidance fell to about $4.80 per share from $5.32 to $5.40.
Deteriorating Forecasts
Analysts have been slashing their numbers. The Zacks Consensus Estimate for 2026 has fallen 10.81% over the prior 60 days to $4.95 per share, while the 2027 consensus dropped nearly 30% to $4.12 — a projected decline of nearly 17% from this year.
Some on the Street are already further along. BofA Securities downgraded the stock to Underperform and cut its 2027 estimate to $3.90 from $5.90, while RBC moved to Sector Perform and characterized the sales weakness as company-specific rather than cyclical. Stifel, initiating with a Hold, estimates the January price reset will cost more than $100 million and expects EBIT margin to settle in the low 5% range.
Missing expectations, cutting guidance and watching forward estimates fall across every period is a recipe for stock price underperformance. These are exactly the trends that the bears like to see.
Technical Outlook
SFM () stock is in a well-defined downtrend. Shares gapped sharply lower on the October report and have spent the weeks since trading near their lows rather than recovering any of the lost ground. Both the 50-day (blue line) and 200-day (red line) moving averages are sloping downward, and the stock sits well beneath each of them.
Shares would need to reclaim both moving averages and show a genuine turn in earnings estimate revisions to warrant taking any long positions in the stock.
Final Thoughts
Whole Foods is growing in overlapping markets, and conventional grocers have spent years expanding their natural and organic assortments. Sprouts is cutting prices into a fight it no longer controls.
Leadership is also in transition. President and COO Nick Konat takes over as CEO on January 4th, the same month the national pricing strategy launches, with Jack Sinclair moving to executive chairman. A new CEO inheriting a margin reset and a February guidance call is not a setup that typically produces upside surprises.
None of this is an indictment of the brand. Sprouts has a differentiated format, a strong private label and a new-store engine that still produces high returns. But a deteriorating fundamental and technical backdrop, membership in a weak industry group, and falling future earnings estimates will likely serve as a ceiling on any potential rallies.
Additional content:
Cybersecurity Stocks Gain on AI Boom: Are Valuations Too High?
Cybersecurity stocks are back in focus as businesses and governments face increasingly sophisticated cyberattacks, growing artificial intelligence (AI)-related security risks and mounting pressure to protect sensitive data. The rapid adoption of generative AI, cloud computing and connected digital infrastructure has expanded the potential attack surface, making cybersecurity spending an increasingly important business priority.
The growing use of AI by cybercriminals is another significant concern. Automated phishing, identity theft, ransomware and more sophisticated attacks are raising the stakes for organizations. At the same time, companies are investing in AI-powered security platforms to detect threats faster, automate responses and strengthen network protection. This creates opportunities for established cybersecurity providers as well as emerging technology specialists.
Why Are Cybersecurity Stocks in the News?
On Nov. 18, U.S. Homeland Security Secretary Markwayne Mullin warned about the growing threat of AI-powered cyberattacks against critical U.S. infrastructure. The warning prompted investors to reassess the industry's growth prospects. Palo Alto Networks, Inc., CrowdStrike Holdings, Inc. and Fortinet, Inc. gained 9.9%, 8% and 5.9%, respectively, even as the broader market weakened.
The positive sentiment received further support from Palo Alto Networks' quarterly results, announced after market close. The company reported first-quarter fiscal 2027 revenue of $3.45 billion, up 39% year over year, beating the Zacks Consensus estimate of $3.31 billion. The company also reported earnings of $1.05 per share, beating the Zacks Consensus Estimate of 97 cents. It raised its full-year revenue outlook and announced a $4.5 billion acquisition of Applied Compute to strengthen its AI security capabilities.
Stocks of CrowdStrike, Palo Alto and Fortinet have advanced 110.9%, 100.6% and 68.1% year to date against a 64% advance for the Zacks Security industry, which they belong to. While PANW and FTNT carry a Zacks Rank #3 (Hold), CRWD has a #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
What Lies Ahead for Cybersecurity Stocks?
The industry's long-term prospects remain encouraging. According to a Boston Consulting Group survey, more than 80% of cybersecurity leaders are increasing spending, while nearly nine in 10 organizations experienced cyberattacks over the past year. AI is simultaneously creating new vulnerabilities and enabling more sophisticated attacks, increasing demand for cloud security, identity protection and automated threat detection.
However, investors should remain selective. Rising competition, elevated valuations, customer budget constraints and pressure to demonstrate tangible returns could create volatility. Companies offering differentiated AI-powered security platforms, strong recurring revenues and effective threat detection capabilities are better positioned to capitalize on rising demand.
Bottom Line
Cybersecurity remains a compelling long-term growth theme. Recent developments reinforce the industry's importance, although investors should prioritize sustainable revenue growth and reasonable valuations over short-term momentum.
Image: Bigstock
Humana and Sprouts Farmers Market have been highlighted as Zacks Bull and Bear of the Day
For Immediate Release
Chicago, IL – November 20, 2026 – Zacks Equity Research shares Humana (HUM - Free Report) as the Bull of the Day and Sprouts Farmers Market (SFM - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Palo Alto Networks, Inc. (PANW - Free Report) , CrowdStrike Holdings, Inc. (CRWV - Free Report) and Fortinet, Inc. (FTNT - Free Report)
Here is a synopsis of all three stocks.
Bull of the Day:
Humana, a Zacks Rank #1 (Strong Buy), has gone from the most beaten-down name in managed care to one of the market's best performers in the span of a single year.
The company that investors abandoned over a collapse in its Medicare Advantage Star Ratings has spent 2026 methodically repairing the problem, and the evidence is now showing up in both the earnings estimates and the stock.
Shares have gained roughly 48% year to date and set a new 52-week high earlier this week, leaving both the Zacks Medical sector and the broader HMO group well behind. A stock that rallies this hard while analysts are still raising their numbers is precisely the combination we look for in a market leader.
Humana is part of the Zacks Medical – HMOs industry group, which currently ranks in the top 12% out of approximately 250 Zacks Ranked Industries. Because it is ranked in the top half of all Zacks Ranked Industries, we expect this group to outperform over the next 3 to 6 months.
Stocks in this industry are projected to experience above-average earnings growth, which should serve as a powerful foundation to higher stock prices over time.
Historical research studies suggest that approximately half of a stock's price appreciation is due to its industry grouping. In fact, the top 50% of Zacks Ranked Industries outperforms the bottom 50% by a factor of more than 2 to 1.
It's no secret that investing in stocks that are part of leading industry groups can give us a leg up relative to the market. By focusing on leading stocks within the top 50% of Zacks Ranked Industries, we can dramatically improve our odds of success.
Company Description
Humana is one of the largest Medicare Advantage insurers in the United States. The company operates through two segments. Its Insurance segment offers Medicare Advantage, stand-alone Medicare Part D prescription drug plans and Medicaid coverage, while its CenterWell segment provides senior-focused primary care, home health and pharmacy services.
That combination makes Humana unusually concentrated in the Medicare population, which is both its greatest source of growth and the reason it suffered so badly when its quality scores slipped.
The Star Ratings story is the heart of this turnaround. Medicare pays quality bonuses to plans rated four stars or higher, and Humana's ratings deteriorated sharply in the 2025 cycle, creating a revenue headwind that has weighed on 2026 earnings. Management responded with an operational overhaul aimed at quality metrics, and the payoff arrived in October.
Based on final 2027 Star Ratings data from CMS, Humana posted a member-weighted rating of 4.17 — approaching the best in its history — and exceeded its goal of top-quartile results, defined as Stars revenue per member at least 10% above the median of Centene, CVS, Elevance, HCSC and UnitedHealth. Those ratings determine bonus payments in 2028, giving investors a clear line of sight on a meaningful tailwind.
CenterWell continues to build quietly underneath. Senior primary care added roughly 146,800 patients this year, a 30% increase that includes the MaxHealth acquisition, while Medicaid membership grew about 7% and now spans 13 states.
A Smaller Loss and a Higher Floor
Humana reported third-quarter results on November 6th that beat on both lines. The company posted an adjusted loss of $0.70 per share against the Zacks Consensus Estimate for a loss of $1.03, a surprise of roughly 32%, and it has now topped the consensus in each of the last four quarters. Revenue climbed about 26% to $41.2 billion, ahead of expectations near $40.9 billion.
The cost line drove the beat. The Insurance segment benefit ratio came in at 93.7%, better than management's guidance of slightly above 94%, and the consolidated adjusted operating cost ratio improved to 11.2% from 11.8% a year earlier. Medical cost trend is running at the low end of the expected 7% to 8% range for 2026, and management says individual Medicare Advantage pretax margin is on track to double this year excluding the Stars headwind.
Management raised its 2026 adjusted earnings floor to at least $9.50 per share from $9.00. Just as important for next year, the company now expects 2027 Medicare Advantage membership to grow, a reversal from its earlier flat-to-down view, with retention and new sales in the current enrollment period running ahead of plan.
Analysts have moved higher with management. The Zacks Consensus Estimate for 2026 stands at $9.52 per share, having climbed more than 4% over the past three months. The more striking figure is next year: the 2027 consensus sits at $17.26, which would represent growth of more than 81% on revenue of roughly $171.5 billion. Estimates rising for both the current year and the recovery year are the engine behind the Zacks Rank #1.
Let's Get Technical
Humana shares have been in a persistent uptrend throughout 2026, trading above an upward-sloping 200-day (red line) moving average and carving out a steady series of higher highs and higher lows. A recent pullback presents an intriguing buying opportunity.
Only stocks in genuinely powerful uptrends make this type of move and sustain it. This is the kind of name we want in the portfolio — one that is trending well and receiving positive earnings estimate revisions at the same time.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. As long as that trend remains intact and Humana continues to deliver earnings beats, the stock should continue its bullish run.
Bottom Line
Backed by a leading industry group, four straight earnings beats, a raised guidance floor and a Star Ratings recovery that sets up a multi-year earnings rebuild, it isn't difficult to see why this company is a compelling investment right now. Humana carries a Zacks Rank #1 (Strong Buy) driven by favorable estimate momentum, along with an 'A' Zacks VGM Style Score.
Robust fundamentals combined with a strong technical trend certainly justify adding shares to the mix. If you haven't already done so, be sure to put HUM on your watchlist.
Bear of the Day:
Sprouts Farmers Market operates specialty grocery stores focused on fresh, natural and organic food across the United States. The company ended its most recent quarter with 504 stores in 25 states, built around a produce-centric layout and a growing private label program.
For several years, Sprouts was one of the best stories in food retail. Its health-and-wellness positioning attracted a loyal, higher-income customer, its smaller-format stores generated strong returns, and steady comparable sales growth paired with an aggressive opening schedule earned the stock a premium multiple.
That story has broken down in 2026. Traffic is falling, the customer is migrating toward value retailers, and management has concluded that the only way to win shoppers back is to invest heavily in price. That may well be the right strategic call, but it comes at a direct cost to margins, and the earnings outlook is being reset accordingly.
The Zacks Rundown
Sprouts has been underperforming the market badly. A Zacks Rank #5 (Strong Sell), the stock has fallen roughly 41% year to date and recently traded under $50, registering a 52-week low. Shares collapsed roughly 23% in a single session following the third-quarter report on October 29th.
The company is part of the Zacks Food – Natural Foods Products industry group, which currently ranks in the bottom 6% out of approximately 250 industries. Because this industry is ranked in the bottom half of all Zacks Ranked Industries, we expect it to underperform the market over the next 3 to 6 months, just as it has over the past year.
While individual stocks have the ability to outperform even when included in weak industries, their industry association serves as a headwind for any potential rallies. Stocks in this group are also expected to post below-average earnings growth. With much better alternatives in the current market environment, this stock should be avoided.
Traffic Is the Problem
Sprouts reported third-quarter results that missed on both lines. Earnings of $1.21 per share came in just below the $1.22 Zacks Consensus Estimate and slipped from the year-ago quarter, while revenue of $2.30 billion grew 4.7% but fell about 1% short of expectations. Revenue growth came entirely from new stores, with a record 15 openings in the quarter.
The underlying store base went backward. Comparable store sales fell 0.9%, as comparable transactions dropped 3.3% and were only partially offset by a 2.5% increase in average basket size. Management said comps softened through August and September and did not recover as year-over-year comparisons eased, a detail that argues against a temporary disruption.
Margins compressed across the board. Gross margin fell 50 basis points to 38.2% on higher shrink and elevated fuel costs, while EBIT margin declined roughly 60 basis points to 6.6% and operating income fell 2.9%. Management noted that weakness is concentrated among less-engaged, somewhat lower-income customers, but also acknowledged modest softening among its core shoppers — the customers Sprouts can least afford to lose.
The guidance reset is where the real damage was done. Full-year comparable sales are now expected to decline about 1.7%, down from a prior range of negative 0.5% to positive 0.5%. Net sales growth was cut to about 4.3% from 5.5% to 6.5%, and earnings guidance fell to about $4.80 per share from $5.32 to $5.40.
Deteriorating Forecasts
Analysts have been slashing their numbers. The Zacks Consensus Estimate for 2026 has fallen 10.81% over the prior 60 days to $4.95 per share, while the 2027 consensus dropped nearly 30% to $4.12 — a projected decline of nearly 17% from this year.
Some on the Street are already further along. BofA Securities downgraded the stock to Underperform and cut its 2027 estimate to $3.90 from $5.90, while RBC moved to Sector Perform and characterized the sales weakness as company-specific rather than cyclical. Stifel, initiating with a Hold, estimates the January price reset will cost more than $100 million and expects EBIT margin to settle in the low 5% range.
Missing expectations, cutting guidance and watching forward estimates fall across every period is a recipe for stock price underperformance. These are exactly the trends that the bears like to see.
Technical Outlook
SFM () stock is in a well-defined downtrend. Shares gapped sharply lower on the October report and have spent the weeks since trading near their lows rather than recovering any of the lost ground. Both the 50-day (blue line) and 200-day (red line) moving averages are sloping downward, and the stock sits well beneath each of them.
Shares would need to reclaim both moving averages and show a genuine turn in earnings estimate revisions to warrant taking any long positions in the stock.
Final Thoughts
Whole Foods is growing in overlapping markets, and conventional grocers have spent years expanding their natural and organic assortments. Sprouts is cutting prices into a fight it no longer controls.
Leadership is also in transition. President and COO Nick Konat takes over as CEO on January 4th, the same month the national pricing strategy launches, with Jack Sinclair moving to executive chairman. A new CEO inheriting a margin reset and a February guidance call is not a setup that typically produces upside surprises.
None of this is an indictment of the brand. Sprouts has a differentiated format, a strong private label and a new-store engine that still produces high returns. But a deteriorating fundamental and technical backdrop, membership in a weak industry group, and falling future earnings estimates will likely serve as a ceiling on any potential rallies.
Additional content:
Cybersecurity Stocks Gain on AI Boom: Are Valuations Too High?
Cybersecurity stocks are back in focus as businesses and governments face increasingly sophisticated cyberattacks, growing artificial intelligence (AI)-related security risks and mounting pressure to protect sensitive data. The rapid adoption of generative AI, cloud computing and connected digital infrastructure has expanded the potential attack surface, making cybersecurity spending an increasingly important business priority.
The growing use of AI by cybercriminals is another significant concern. Automated phishing, identity theft, ransomware and more sophisticated attacks are raising the stakes for organizations. At the same time, companies are investing in AI-powered security platforms to detect threats faster, automate responses and strengthen network protection. This creates opportunities for established cybersecurity providers as well as emerging technology specialists.
Why Are Cybersecurity Stocks in the News?
On Nov. 18, U.S. Homeland Security Secretary Markwayne Mullin warned about the growing threat of AI-powered cyberattacks against critical U.S. infrastructure. The warning prompted investors to reassess the industry's growth prospects. Palo Alto Networks, Inc., CrowdStrike Holdings, Inc. and Fortinet, Inc. gained 9.9%, 8% and 5.9%, respectively, even as the broader market weakened.
The positive sentiment received further support from Palo Alto Networks' quarterly results, announced after market close. The company reported first-quarter fiscal 2027 revenue of $3.45 billion, up 39% year over year, beating the Zacks Consensus estimate of $3.31 billion. The company also reported earnings of $1.05 per share, beating the Zacks Consensus Estimate of 97 cents. It raised its full-year revenue outlook and announced a $4.5 billion acquisition of Applied Compute to strengthen its AI security capabilities.
Stocks of CrowdStrike, Palo Alto and Fortinet have advanced 110.9%, 100.6% and 68.1% year to date against a 64% advance for the Zacks Security industry, which they belong to. While PANW and FTNT carry a Zacks Rank #3 (Hold), CRWD has a #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
What Lies Ahead for Cybersecurity Stocks?
The industry's long-term prospects remain encouraging. According to a Boston Consulting Group survey, more than 80% of cybersecurity leaders are increasing spending, while nearly nine in 10 organizations experienced cyberattacks over the past year. AI is simultaneously creating new vulnerabilities and enabling more sophisticated attacks, increasing demand for cloud security, identity protection and automated threat detection.
However, investors should remain selective. Rising competition, elevated valuations, customer budget constraints and pressure to demonstrate tangible returns could create volatility. Companies offering differentiated AI-powered security platforms, strong recurring revenues and effective threat detection capabilities are better positioned to capitalize on rising demand.
Bottom Line
Cybersecurity remains a compelling long-term growth theme. Recent developments reinforce the industry's importance, although investors should prioritize sustainable revenue growth and reasonable valuations over short-term momentum.